News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Relypsa, Inc. Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease



6/28/2011 9:38:37 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies. The trial, also known as AMETHYST-DN, will evaluate the safety and efficacy of RLY5016 in reducing high potassium levels (hyperkalemia) in patients who have moderate to severe kidney impairment (eGFR < 60 mL/min) and are being treated with renin-angiotensin-aldosterone-system (RAAS) inhibitors, including angiotensin receptor blockers (ARBs).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES